CStone Pharmaceuticals (HKG:2616)
Hong Kong · Delayed Price · Currency is HKD 6.02
-0.15 (-2.35%)
Sep 10, 2026, 1:15 PM HKT
CStone Pharmaceuticals Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 425.23 | 269.58 | 407.21 | 463.84 | 481.36 | 243.72 |
| 425.23 | 269.58 | 407.21 | 463.84 | 481.36 | 243.72 | |
Revenue Growth | 110.00% | -33.80% | -12.21% | -3.64% | 97.51% | -76.54% |
Cost of Revenue | 187 | 218.34 | 167.05 | 159.55 | 202.99 | 106.83 |
Gross Profit | 238.24 | 51.25 | 240.15 | 304.3 | 278.38 | 136.89 |
Selling, General & Admin | 217.59 | 172.36 | 211.58 | 382.06 | 576.36 | 661.38 |
Research & Development | 395.86 | 294.71 | 123.93 | 501.4 | 614.16 | 1,305 |
Operating Expenses | 613.45 | 467.07 | 335.51 | 883.46 | 1,191 | 1,966 |
Operating Income | -375.22 | -415.83 | -95.36 | -579.16 | -912.15 | -1,829 |
Interest Expense | -11.49 | -13.27 | -15.17 | -11.82 | -8.48 | -2.24 |
Interest & Investment Income | 18.68 | 10.39 | 12.67 | 24.89 | 9.67 | 9.8 |
Currency Exchange Gain (Loss) | -38.79 | -2.89 | -2.8 | 20.36 | 61.49 | -69.13 |
Other Non Operating Income (Expenses) | 13.52 | 15.16 | 13.44 | 25.71 | 8.71 | 36.02 |
EBT Excluding Unusual Items | -393.3 | -406.44 | -87.22 | -520.02 | -840.75 | -1,855 |
Gain (Loss) on Sale of Investments | 3.27 | -0.71 | 6.36 | 0.3 | -61.93 | -64.2 |
Gain (Loss) on Sale of Assets | - | - | 0.38 | 178.89 | - | -0.9 |
Asset Writedown | -16.01 | -16.8 | -10.73 | -26.4 | - | - |
Pretax Income | -406.04 | -423.94 | -91.21 | -367.23 | -902.68 | -1,920 |
Income Tax Expense | 13.06 | 13.06 | - | - | - | - |
Earnings From Continuing Operations | -419.1 | -437 | -91.21 | -367.23 | -902.68 | -1,920 |
Net Income | -419.1 | -437 | -91.21 | -367.23 | -902.68 | -1,920 |
Net Income to Common | -419.1 | -437 | -91.21 | -367.23 | -902.68 | -1,920 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 1,492 | 1,388 | 1,276 | 1,263 | 1,173 | 1,165 |
Shares Outstanding (Diluted) | 1,492 | 1,388 | 1,276 | 1,263 | 1,173 | 1,165 |
Shares Change | 15.16% | 8.79% | 1.04% | 7.69% | 0.66% | 11.39% |
EPS (Basic) | -0.28 | -0.31 | -0.07 | -0.29 | -0.77 | -1.65 |
EPS (Diluted) | -0.28 | -0.31 | -0.07 | -0.29 | -0.77 | -1.65 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | -327.75 | -303.21 | -588.86 | -610.74 | -1,575 |
Free Cash Flow Per Share | - | -0.24 | -0.24 | -0.47 | -0.52 | -1.35 |
Gross Margin | 56.03% | 19.01% | 58.98% | 65.60% | 57.83% | 56.17% |
Operating Margin | -88.24% | -154.25% | -23.42% | -124.86% | -189.49% | -750.64% |
Profit Margin | -98.56% | -162.10% | -22.40% | -79.17% | -187.53% | -787.84% |
Free Cash Flow Margin | - | -121.58% | -74.46% | -126.95% | -126.88% | -646.26% |
EBITDA | -363.38 | -403.85 | -82.06 | -560.24 | -895.41 | -1,821 |
EBITDA Margin | -85.45% | -149.80% | -20.15% | -120.78% | -186.01% | - |
D&A For EBITDA | 11.84 | 11.98 | 13.3 | 18.93 | 16.74 | 8.76 |
EBIT | -375.22 | -415.83 | -95.36 | -579.16 | -912.15 | -1,829 |
EBIT Margin | -88.24% | -154.25% | -23.42% | -124.86% | -189.49% | - |